Novartis Pharmaceuticals Canada Inc.
Industry / private company
Location:
Mississauga,
Canada (CA)
ROR: https://ror.org/05afs3z13
Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison (2023)
Rugo HSS, Harmer V, O'Shaughnessy J, Jhaveri K, Tolaney SMM, Cardoso F, Bardia A, et al.
Journal article
Matching adjusted indirect comparison of PFS & OS comparing ribociclib plus letrozole vs palbociclib plus letrozole as first-line treatment of HR+/HER2-ABC: Analysis based on updated PFS & final OS results of MONALEESA-2 & PALOMA-2 (2022)
Jhaveri K, O'Shaughnessy J, Fasching P, Cardoso F, Tolaney S, Hamilton E, Sharma VK, et al.
Conference contribution
Assessment of side effects (SEs) impacting quality of life (QoL) in patients (pts) undergoing treatment (tx) for advanced breast cancer (ABC) in clinical practice: A real-world (RW) multi-country survey (2022)
Cardoso F, Rihani J, Aubel D, De Courcy J, Harmer V, Harbeck N, Casas A, et al.
Conference contribution